Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | hexokinase 1 | 0.0828 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase type 2 | 0.0828 | 1 | 0.5 |
Treponema pallidum | hexokinase (hxk) | 0.0828 | 1 | 0.5 |
Echinococcus granulosus | hexokinase type 2 | 0.0828 | 1 | 0.5 |
Trypanosoma brucei | hexokinase, putative | 0.0828 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.0828 | 1 | 1 |
Echinococcus multilocularis | hexokinase | 0.0828 | 1 | 0.5 |
Onchocerca volvulus | 0.0828 | 1 | 1 | |
Plasmodium vivax | hexokinase, putative | 0.0828 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.0828 | 1 | 0.5 |
Leishmania major | hexokinase, putative | 0.0828 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0828 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase type II | 0.0828 | 1 | 1 |
Toxoplasma gondii | hexokinase | 0.0828 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0564 | 0.1468 | 0.1468 |
Echinococcus granulosus | hexokinase | 0.0828 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0828 | 1 | 0.5 |
Trypanosoma cruzi | hexokinase, putative | 0.0828 | 1 | 0.5 |
Trypanosoma brucei | hexokinase | 0.0828 | 1 | 0.5 |
Schistosoma mansoni | hexokinase | 0.0828 | 1 | 0.5 |
Trypanosoma brucei | hexokinase | 0.0828 | 1 | 0.5 |
Onchocerca volvulus | 0.0828 | 1 | 1 | |
Plasmodium falciparum | hexokinase | 0.0828 | 1 | 0.5 |
Onchocerca volvulus | 0.0828 | 1 | 1 | |
Echinococcus granulosus | hexokinase | 0.0828 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 2 | 0.0828 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.0828 | 1 | 1 |
Brugia malayi | Hexokinase family protein | 0.0828 | 1 | 1 |
Trypanosoma cruzi | hexokinase, putative | 0.0828 | 1 | 0.5 |
Leishmania major | hexokinase, putative | 0.0828 | 1 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.